Celgene Corporation

États‑Unis d’Amérique


Commandez votre montre hebdomadaire Celgene Corporation
Quantité totale PI 1 397
Quantité totale incluant filiales 1 969 (+ 572 pour les filiales)
Rang # Quantité totale PI 968
Note d'activité PI 3,6/5.0    810
Rang # Activité PI 901
Activité incl filiales 3,3/5.0    885
Symbole boursier CELG (nasdaq)
ISIN US1510201049
Capitalisation 77,036M  (USD)
Industrie Drug Manufacturers - Major
Secteur Healthcare
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

369 181
99 207
331 69
141
 
Dernier brevet 2025 - Solid forms comprising (s)-4-(4-...
Premier brevet 1981 - Production of muconic acid
Dernière marque 2025 - YONMEZI
Première marque 1996 - Rev

Filiales

20 subsidiaries with IP (552 patents, 20 trademarks)

9 subsidiaries without IP

 S'inscrire grtuitement pour accéder à la liste des filiales

Industrie (Classification de Nice)

Derniers inventions, produits et services

2025 P/S Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases,...
P/S Pharmaceutical and biological preparations for human use.
P/S Pharmaceutical and biological preparations for human use.
Invention Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl...
P/S Pharmaceutical preparations for the treatment and prevention of oncological, hematological, metab...
Invention Modulators of bcl6 as ligand directed degraders. Provided herein are compounds and compositions ...
Invention Salts and solid forms of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidi...
Invention Heterocyclic compounds and their use for treatment of helminthic infections and diseases. Provid...
Invention Pharmaceutical compositions comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morphol...
2024 Invention Therapy for the treatment of multiple myeloma. Provided herein are methods of treating and/or man...
Invention Antiproliferative compounds and second active agents for combined use. Provided herein are metho...
P/S Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinen...
P/S Pharmaceutical and biological preparations for human use in the fields of hematology, oncology an...
Invention Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-mor...
Invention Uses of anti-bcma chimeric antigen receptors. Provided herein are uses of anti-B cell maturation...
Invention Combination therapies comprising apremilast and tyk2 inhibitors. Provided herein are methods of ...
Invention Oral formulations of cytidine analogs and methods of use thereof. The present disclosure provide...
Invention Cereblon binding compounds, compositions thereof, and methods of treatment therewith. Provided h...
Invention Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin...
Invention Methods for treating systemic lupus erythematosus and the use of biomarkers as a predictor of cli...
Invention Antiproliferative compounds and bispecific antibody against bcma and cd3 for combined use. Provi...
Invention Tablet compositions. Provided herein is a tablet comprising 2-methyl-1-[(4-[6-(trifluoromethyl)p...
Invention Heteroaryl compounds as ligand directed degraders of irak4. Provided herein are compounds and com...
Invention Transgenic mouse expressing human cereblon. Provided are transgenic mice whose genome comprises ...
Invention Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatmen...
Invention Assessment of bcma in biological samples. Provided herein are methods for detection of soluble B-...
Invention Compounds and compositions for selective degradation of engineered proteins. Provided herein are...
Invention Compounds and compositions for selective degradation of engineered proteins. Provided herein are ...
Invention Compounds and compositions useful as degraders of mk2 kinase. The present disclosure provides com...
Invention Processes for the preparation of (s)-tert-butyl 4,5-diamino-5-oxopentanoate. Provided are process...
Invention Combination therapies using an anti-bcma antibody drug conjugate (adc) in combination with a gamm...
Invention Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases. ...
2023 Invention Substituted imidazo-based compounds as ligand directed degraders of irak3. Provided herein are co...
Invention Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and met...
Invention Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior ther...
Invention Methods and uses related to t cell therapy and production of same. Provided herein are uses of T...
Invention Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma. Pro...
2022 Invention Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases. Pr...
Invention Modulators of camkk2 as ligand directed degraders. Provided herein are compounds of formula (I) ...
Invention Process for preparing histone demethylase inhibitors. Provided herein are methods for preparing ...
Invention Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoaze...
Invention Methods of treating multiple myeloma using combination therapy. Provided herein are methods of u...
Invention Pkc-theta modulators. Disclosed are compounds, compositions and methods for treating disease, sy...
Invention Methods of treating b-cell lymphoma using combination therapy. Provided herein are methods of us...
Invention Treatment of cancer with kdm4 inhibitors. Provided herein are compositions and methods for the t...
Invention Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation ...
Invention Methods for treating multiple myeloma. Provided herein are methods of treating multiple myeloma,...
2021 Invention Actriib ligand trap compositions and uses thereof. The present application relates to recombinant...